Congcong Xu

Congcong Xu

Auto-generated profile, based on publicly available information

Congcong Xu

The First Affiliated Hospital, International College of Pharmaceutical Innovation Soochow University Suzhou China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2024 in Science Advances
Verified
Journal Article
Open access
TFTing Fan
Ting Fan
CXCongcong Xu
Congcong Xu
JWJichuan Wu
Jichuan Wu
YCYihua Cai
Yihua Cai
WCWanlu Cao
Wanlu Cao
CDChunyan Dong
Chunyan Dong
MRNA neoantigen cancer vaccine inducing neoantigen-specific T cell responses holds great promise for cancer immunotherapy; however, its clinical translation remains challenging because of suboptimal neoantigen prediction accuracy and low delivery efficiency, which compromise the in vivo therapeutic efficacy. We present a lipopolyplex (LPP)–formulated mRNA cancer vaccine encoding tandem neoantigens as a cancer therapeutic regimen. The LPP-formulated mRNA vaccines elicited robust neoantigen-specific CD8 + T cell responses in three syngeneic murine tumor models (CT26, MC38, and B16F10) to suppress tumor growth. Prophylactic cancer vaccine treatment completely prevented tumor development, and long-lasting memory T cells protected mice from tumor cell rechallenge. Combining the vaccine with immune checkpoint inhibitor further boosted the antitumor activity. Of note, LPP-based personalized cancer vaccine was administered in two cancer patients and induced meaningful neoantigen-specific T cell and clinical responses. In conclusion, we demonstrated that the LPP-based mRNA vaccine can elicit strong antitumor immune responses, and the results support further clinical evaluation of the therapeutic mRNA cancer vaccine.

15 February 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
CXCongcong Xu
Congcong Xu
YZYating Zhuo
Yating Zhuo
YLYunyao Liu
Yunyao Liu
HCHao Chen
Hao Chen
Background: Cutaneous squamous cell carcinoma (cSCC) is a common cutaneous cancer with increasing incidence. Itraconazole has been identified as a potential anticancer drug candidate. However, the role of itraconazole in cSCC was still unclear. Our objective is exploring the therapeutic potential of itraconazole in cSCC and investigate its molecular mechanism.Methods: The anti-proliferation effect of itraconazole was tested with CCK-8 assay and clone formation assay. Cell cycle distribution and apoptosis rate were detected using flow cytometry and TUNEL assay, respectively. Transcriptomic and proteomic analyses were used to explore the underlying anti-cancer mechanism. Luciferase reporter assay was used for promoter activity. Reactive oxygen species (ROS), lipid peroxidation and iron accumulation were examined. The in vivo efficacy of itraconazole was assessed in a xenograft model.Results: Itraconazole inhibited the cell proliferation, induced apoptosis and blocked cell cycle of cSCC cells. An integrated analysis of transcriptomic and proteomic analyses identified that 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and acyl-CoA synthetase long-chain family member 4 (ACSL4) were significantly upregulated in A431 cells treated with itraconazole. HMGCS1 silencing reversed the antiproliferative activity of itraconazole in A431 cells. Dual-luciferase assay showed that itraconazole could promote HMGCS1 transcription. HMGCS1 silencing abated the expression of ACSL4 in A431 cells. The level of ROS, lipid peroxidation, as well as iron accumulation were increased by itraconazole. Moreover, treatment with itraconazole impeded tumor growth in A431-bearing mice.Conclusion: We proved itraconazole inhibits the growth of cSCC by regulating HMGCS1/ACSL4 axis.

1 November 2025 in Journal of Controlled Release
Verified
Journal Article
Closed access
TSTianyu Shi
Tianyu Shi
YLYao Li
Yao Li
CDChangchang Deng
Changchang Deng
QRQiongzhe Ren
Qiongzhe Ren
CXCongcong Xu
Congcong Xu
ZZZhiyuan Zhong
Zhiyuan Zhong

7 April 2025 in Nano Today
Verified
Journal Article
Closed access
RYRuonan Ye
Ruonan Ye
QRQiongzhe Ren
Qiongzhe Ren
LCLimin Chang
Limin Chang
SZSiqi Zhang
Siqi Zhang
CDChangchang Deng
Changchang Deng
ZZZhiyuan Zhong
Zhiyuan Zhong

10 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
CXCongcong Xu
Congcong Xu
CPChengtao Pu
Chengtao Pu
RCRuofan Chen
Ruofan Chen
WWWeiyun Wang
Weiyun Wang
FJFan Jiang
Fan Jiang
HLHangwen Li
Hangwen Li
Synthetic circular RNA (circRNA) has emerged as a promising platform for vaccine and therapeutic development, featuring its uniqueness in a closed-loop structure, cap-independent translation mechanism, and prolonged expression. However, the rational design of a circRNA sequence to jointly improve its stability and protein coding potential remains challenging. In this study, we present circDesign, an efficient algorithm to achieve the optimal design of circRNA by ensuring optimized folding of each segment, which leads to enhanced circularization efficiency, stability, and translatability. Using rabies virus glycoprotein (RABV-G) as the model antigen, we demonstrated that circDesign-generated circRNAs exhibited higher stability and protein translation efficiency in vitro and in vivo compared to other codon adaptation index (CAI)-optimized sequences, thus leading to enhanced in vivo immunogenicity. Ribosome and polysome profiling further revealed that an intact internal ribosome entry site (IRES) structure is critical for efficient translation. By intentionally disrupting the IRES motifs, we observed that the resulting circRNA sequences had lower translatability compared to circDesign-generated sequences. Taken together, our circular RNA design algorithm provides a general strategy to leverage the capability of circRNA as next-generation vaccines or therapeutics.

28 May 2020 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
PDF file
CXCongcong Xu
Congcong Xu
JLJiao Li
Jiao Li
LSLi Su
Li Su
HTHua Tang
Hua Tang
WZWen Zhang
Wen Zhang